Tracking and predicting chemotherapy-related nerve damage in children with acute lymphoblastic leukemia
Official title: Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia: A Perspective Longitudinal Study
Run by The Hong Kong Polytechnic University · NCT07326930 · Data updated 2026-11-12
Researchers will track how vincristine-related nerve damage develops over time in children (ages 8–17) with acute lymphoblastic leukemia and try to identify factors that predict different symptom patterns.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 8 Years to 17 Years |
| Sex | All |
| Enrollment | 173 (estimated) |
| Sponsor | The Hong Kong Polytechnic University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Zhengzhou, Henan and 2 other locations) |
| Status | Recruiting |
| Started | June 2, 2025 |
| Main results expected | January 7, 2026 |
| Study ends | January 7, 2026 |
| Registry record updated | January 8, 2026 |
| Trial ID | NCT07326930 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 8–17 years with a diagnosis of acute lymphoblastic leukemia who will receive vincristine per the CCCG-ALL-2020 protocol, are cognitively able to report symptoms, and whose parents and the child provide informed assent/consent.
✕Probably not a fit
Children with preexisting neuropathy from other diseases, neuromuscular disorders, CNS or secondary cancers, severe organ failure, or those enrolled in other experimental interventions altering neuropathy risk are unlikely to gain benefit from this observational project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective longitudinal observational study of children with acute lymphoblastic leukemia who receive vincristine according to the CCCG-ALL-2020 protocol. Peripheral neuropathy symptoms are measured repeatedly at standardized times after successive vincristine doses (one week after the 1st–4th doses, then at two-week intervals up to the seventh follow-up). Baseline data including demographics, clinical features, physical symptoms, nutrition, psychological distress, sleep quality, physical activity, social support, and coping strategies are collected. Trajectory modeling will be used to identify distinct symptom course patterns and examine which baseline factors predict membership in those trajectories.
Why it matters
Potential benefit: If successful, the results could help clinicians identify children at higher risk for prolonged or severe neuropathy and tailor monitoring or supportive care to reduce long-term symptoms.
How similar studies have gone: Prior research has documented vincristine-induced neuropathy and some risk factors in children, but detailed longitudinal trajectory modeling of symptom courses in this specific population remains relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosed with acute lymphoblastic leukemia * aged from 8 to 17 years * will receive vincristine according the Chinese Children's Cancer Group Acute Lymphoblastic Leukemia-2020 Project (CCCG-ALL-2020) * conscious with sufficient cognitive abilities to understand and express their physical state and psychological feelings accurately * written informed assent is obtained from the children and their parents for their participation in the study Exclusion Criteria: * participating other experimental trials, such as electrical stimulation, exercise therapy may improve CIPN symptoms. * with severe complications, including but not limited to significant heart, brain, or lung function failure. * had peripheral neuropathy symptoms caused by other diseases like genetic diseases, spinal cord injury. * had neuromuscular diseases (e.g., traumatic brain injury and cerebral palsy). * had central nervous system cancer or secondary cancer. * had multiple treatment like radiotherapy.
Where it's running
-
The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital,
Zhengzhou, Henan, China Recruiting -
Shanghai Children's Medical Center
Shanghai, China Recruiting -
Shenzhen Children's Hospital
Shenzhen, China Recruiting
Study contacts
- Principal investigator: Ka Yan Ho — The Hong Kong Polytechnic University
- Study coordinator: Ka Yan Ho, PhD
- Email: kyeva.ho@polyu.edu.hk
- Phone: 852-27666417
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes
This study follows children, teens, and young adults with cancer in low- and middle-income countries to see how routine care affects treatment, access, and outcomes over time.
-
First-in-human testing of 4A10 for relapsed or hard-to-treat ALL and lymphoblastic lymphoma
This early-stage trial tests a new antibody therapy called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia or lymphoblastic lymphoma to see if it is safe and how the body handles it.
-
Plasma cell-free DNA in children with ALL to help monitor disease
This study tests whether measuring tumor DNA in blood can help monitor acute lymphoblastic leukemia in kids without needing frequent bone-marrow tests.
-
Laughter and fun yoga to ease chemotherapy pain in children
This tests whether a home-based program of laughter and kid-friendly yoga can lower pain in children aged 2–10 who are receiving chemotherapy for acute lymphoblastic leukemia.
-
Optimizing and Unifying Management of HSCT in Pediatric ALL
This trial tests a harmonized HSCT approach for children and young people with ALL, aiming to reduce transplant-related risks and improve long-term outcomes.
-
Child and Young Adult (CAYA) Cancer Outcomes Review
This project looks at past treatment results to see what affects outcomes for children and young adults (ages 0–21) with leukemia and other cancers treated at participating centers in low- and middle-income countries.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.